An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Sep 2017
At a glance
- Drugs Idelalisib (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 29 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
- 29 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
- 18 Jul 2016 Status changed from recruiting to active, no longer recruiting.